Effect of UDP-glucuronyltransferase1A4 polymorphisms on the pharmacokinetics of Lamotrigine

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-11001686

Enrollment

Unknown

Registered

2011-11-06

Start date

2011-11-06

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Interventions

1:Wild type group were orally administered a single dose of 100 mg lamotrigine

2:Heterozygote were orally administered a single dose of 100 mg lamotrigine

3:Homozygote were orally administered a single dose of 100 mg lamotrigine

Eligibility

Sex/Gender

Male

Age

20 Years to 24 Years

Inclusion criteria

Inclusion criteria: Genotyping

Exclusion criteria

Exclusion criteria: Person failed the physical examination

Design outcomes

Primary

Measure	Time frame
Blood drug concentration of lamotrigine;	—

Countries

China

Contacts

Public ContactHonghao Zhou

hhzhou2003@163.com+86 731 84805380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026